.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Fish and Richardson
Healthtrust
Novartis
Dow
Cerilliant
Colorcon
UBS
US Department of Justice
Accenture

Generated: September 26, 2017

DrugPatentWatch Database Preview

Lantheus Medcl Company Profile

« Back to Dashboard

What is the competitive landscape for LANTHEUS MEDCL, and when can generic versions of LANTHEUS MEDCL drugs launch?

LANTHEUS MEDCL has nine approved drugs.

There are four US patents protecting LANTHEUS MEDCL drugs.

There are seventy-seven patent family members on LANTHEUS MEDCL drugs in thirty-four countries.

Summary for Applicant: Lantheus Medcl

Patents:4
Tradenames:9
Ingredients:8
NDAs:9
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001RXYesYes► Subscribe► SubscribeY ► Subscribe
Lantheus Medcl
XENON XE 133
xenon xe-133
INJECTABLE;INJECTION017283-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Lantheus Medcl
TECHNELITE
technetium tc-99m sodium pertechnetate generator
SOLUTION;INTRAVENOUS017771-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Lantheus Medcl
NEUROLITE
technetium tc-99m bicisate kit
INJECTABLE;INJECTION020256-001Nov 23, 1994RXNoNo► Subscribe► Subscribe► Subscribe
Lantheus Medcl
THALLOUS CHLORIDE TL 201
thallous chloride tl-201
INJECTABLE;INJECTION017806-001Approved Prior to Jan 1, 1982APRXYesYes► Subscribe► Subscribe► Subscribe
Lantheus Medcl
TECHNELITE
technetium tc-99m sodium pertechnetate generator
SOLUTION;INTRAVENOUS017771-002Feb 12, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Lantheus Medcl
XENON XE 133
xenon xe-133
GAS;INHALATION017284-001Approved Prior to Jan 1, 1982RXNoNo► Subscribe► Subscribe► Subscribe
Lantheus Medcl
XENON XE 133
xenon xe-133
GAS;INHALATION017284-002Approved Prior to Jan 1, 1982RXNoNo► Subscribe► Subscribe► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-001Dec 22, 2008DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Lantheus Medcl

Non-Orange Book Patents for Lantheus Medcl

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,011,815Diagnostic imaging contrast agents with extended blood retention► Subscribe
8,747,892Preparation of a lipid blend and a phospholipid suspension containing the lipid blend► Subscribe
8,017,105Diagnostic imaging contrast agents with extended blood retention► Subscribe
7,229,606Diagnostic imaging contrast agents with extended blood retention► Subscribe
8,394,356Diagnostic imaging contrast agents with extended blood retention► Subscribe
7,060,250Diagnostic imaging contrast agents with extended blood retention► Subscribe
8,084,056Preparation of a lipid blend and a phospholipid suspension containing the lipid blend► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Lantheus Medcl Drugs

Country Document Number Estimated Expiration
Canada2211100► Subscribe
Norway321866► Subscribe
Hungary0100206► Subscribe
New Zealand505082► Subscribe
Slovenia1419789► Subscribe
South Africa9600417► Subscribe
Slovenia0806968► Subscribe
Norway20081355► Subscribe
China1177806► Subscribe
Iceland2505► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Lantheus Medcl Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2007 00016Denmark► Subscribe
0736Netherlands► SubscribePRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119
C0028France► SubscribePRODUCT NAME: GADOFOSVESET TRISODIQUE; REGISTRATION NO/DATE: EU/1/05/313/001-009 20051003
2007003Lithuania► SubscribePRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REG NO/DATE: EU/1/05/313/001-009 20051005
C/GB07/031United Kingdom► SubscribePRODUCT NAME: PERFLUTREN-CONTAINING LIPID MICROSPHERES; REGISTERED: UK EU/1/06/361/001 20060920
2007003,C0806968Lithuania► SubscribePRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REGISTRATION NO/DATE: EU/1/05/313/001, 2005 10 05 EU/1/05/313/002, 2005 10 05 EU/1/05/313/003, 2005 10 05 EU/1/05/313/004, 2005 10 05 EU/1/05/313/005, 2005 10 05 EU/1/05/313/006, 2006 10 05 EU/1/05/313/007, 2005 10 05 EU/1/05/313/008, 2005 10 05 EU/1/05/313/00 2005100
00267Netherlands► SubscribePRODUCT NAME: PERFLUTREN BEVATTENDE LIPIDE-MICROBOLLEN; REGISTRATION NO/DATE: EU/1/06/361/001 20060920
C 037/2006Ireland► SubscribeSPC 037/2006: 20070528, EXPIRES: 20201002
0806968/01Switzerland► SubscribeFORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
C/GB07/011United Kingdom► SubscribePRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Novartis
Colorcon
US Army
Fish and Richardson
Express Scripts
Queensland Health
Boehringer Ingelheim
Johnson and Johnson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot